Lysosomal disease with hypertrophic cardiomyopathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:217581
Who is this for?
Show terms as
5Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Lysosomal disease with hypertrophic cardiomyopathy (Orphanet code 217581) is a clinical grouping rather than a single disease entity. It encompasses a set of lysosomal storage disorders that share the prominent feature of hypertrophic cardiomyopathy — a condition in which the heart muscle becomes abnormally thickened, making it harder for the heart to pump blood effectively. Lysosomal storage disorders in this category result from deficiencies in specific lysosomal enzymes or proteins, leading to the accumulation of substrates within cells, particularly affecting cardiac tissue. Notable diseases that fall under this umbrella include Fabry disease, Pompe disease (glycogen storage disease type II), Danon disease, and certain mucopolysaccharidoses, each of which can present with significant cardiac hypertrophy. The body systems affected vary depending on the specific underlying lysosomal disorder but commonly include the cardiovascular system (hypertrophic cardiomyopathy, arrhythmias, heart failure), the musculoskeletal system (myopathy, exercise intolerance), and the nervous system (neuropathy or cognitive involvement in some forms). Additional features may include hepatosplenomegaly, skeletal abnormalities, and respiratory compromise. The severity and age of onset depend on the specific enzyme deficiency and residual enzyme activity. Treatment approaches differ based on the specific lysosomal disease identified. Enzyme replacement therapy (ERT) is available for some conditions, such as Fabry disease and Pompe disease, and can help slow disease progression. Other therapeutic strategies include substrate reduction therapy, pharmacological chaperone therapy, and supportive cardiac management including medications for heart failure and arrhythmias. Genetic counseling is recommended for affected families. Early diagnosis through genetic testing and cardiac imaging is important for optimizing outcomes.

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Lysosomal disease with hypertrophic cardiomyopathy.

View clinical trials →

No actively recruiting trials found for Lysosomal disease with hypertrophic cardiomyopathy at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Lysosomal disease with hypertrophic cardiomyopathy community →

Specialists

5 foundView all specialists →
BM
Barry Greenberg, MD
Specialist
PI on 2 active trials
JM
Joseph Rossano, MD
PHILADELPHIA, PA
Specialist
PI on 2 active trials
PP
Peter Nordbeck, MD, PhD
Specialist
PI on 2 active trials
EP
Elena Biagini, MD, PhD
Chieti, Abruzzo/Chieti
Specialist

Rare Disease Specialist

PI on 2 active trials
UM
Ulla Feldt-Rasmussen, MD,DMSc,Prof
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Lysosomal disease with hypertrophic cardiomyopathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Lysosomal disease with hypertrophic cardiomyopathyForum →

No community posts yet. Be the first to share your experience with Lysosomal disease with hypertrophic cardiomyopathy.

Start the conversation →

Latest news about Lysosomal disease with hypertrophic cardiomyopathy

No recent news articles for Lysosomal disease with hypertrophic cardiomyopathy.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Lysosomal disease with hypertrophic cardiomyopathy

What is Lysosomal disease with hypertrophic cardiomyopathy?

Lysosomal disease with hypertrophic cardiomyopathy (Orphanet code 217581) is a clinical grouping rather than a single disease entity. It encompasses a set of lysosomal storage disorders that share the prominent feature of hypertrophic cardiomyopathy — a condition in which the heart muscle becomes abnormally thickened, making it harder for the heart to pump blood effectively. Lysosomal storage disorders in this category result from deficiencies in specific lysosomal enzymes or proteins, leading to the accumulation of substrates within cells, particularly affecting cardiac tissue. Notable diseas

Which specialists treat Lysosomal disease with hypertrophic cardiomyopathy?

5 specialists and care centers treating Lysosomal disease with hypertrophic cardiomyopathy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.